GAIN THERAPEUTICS, INC Other Noncash Income (Expense)
GAIN THERAPEUTICS, INC (GANX) reported Other Noncash Income (Expense) of -$330.38 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-11
- GAIN THERAPEUTICS, INC other noncash income (expense) for the quarter ending 2026-06-30 was -$99.91K.
- GAIN THERAPEUTICS, INC other noncash income (expense) for the quarter ending 2026-03-31 was -$230.46K.
- GAIN THERAPEUTICS, INC other noncash income (expense) for the quarter ending 2025-12-31 was -$11.19K.
- GAIN THERAPEUTICS, INC other noncash income (expense) for the quarter ending 2025-09-30 was -$10.86K, a 124.59% decline year-over-year.
- GAIN THERAPEUTICS, INC other noncash income (expense) for fiscal 2025 was -$804.94K.
- GAIN THERAPEUTICS, INC other noncash income (expense) for fiscal 2024 was -$143.52K, a 137.45% decline from fiscal 2023.
- GAIN THERAPEUTICS, INC other noncash income (expense) for fiscal 2023 was $383.19K, a 85.24% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC other noncash income (expense) for fiscal 2022 was $206.86K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$99.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$330.38K 10-Q · filed 2026-08-11 | -$341.57K derived: sum of 3 quarters · filed 2026-08-11 | -$352.43K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$230.46K 10-Q · filed 2026-05-11 | -$241.66K derived: sum of 2 quarters · filed 2026-05-11 | -$252.52K derived: sum of 3 quarters · filed 2026-05-11 | -$925.81K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$11.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$22.06K derived: sum of 2 quarters · filed 2026-03-26 | -$695.35K derived: sum of 3 quarters · filed 2026-08-11 | -$804.94K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$10.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$684.15K derived: sum of 2 quarters · filed 2026-08-11 | -$793.74K 10-Q · filed 2025-11-12 | -$1.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$673.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$782.88K 10-Q · filed 2026-08-11 | -$1.34M derived: sum of 3 quarters · filed 2026-08-11 | -$1.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$109.59K 10-Q · filed 2026-05-11 | -$663.58K derived: sum of 2 quarters · filed 2026-05-11 | -$619.39K derived: sum of 3 quarters · filed 2026-05-11 | -$453.26K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$553.98K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$509.80K derived: sum of 2 quarters · filed 2026-03-26 | -$343.67K derived: sum of 3 quarters · filed 2026-03-26 | -$143.52K 10-K · filed 2026-03-26 |
| 2024-09-30 | $44.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $210.31K derived: sum of 2 quarters · filed 2025-11-12 | $410.46K 10-Q · filed 2025-11-12 | $546.16K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $166.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $366.28K 10-Q · filed 2025-08-12 | $501.98K derived: sum of 3 quarters · filed 2025-08-12 | $673.08K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $200.15K 10-Q · filed 2025-05-14 | $335.84K derived: sum of 2 quarters · filed 2025-05-14 | $506.95K derived: sum of 3 quarters · filed 2025-05-14 | $461.10K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $135.70K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $306.81K derived: sum of 2 quarters · filed 2025-03-27 | $260.95K derived: sum of 3 quarters · filed 2025-03-27 | $383.19K 10-K · filed 2025-03-27 |
| 2023-09-30 | $171.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $125.25K derived: sum of 2 quarters · filed 2024-11-14 | $247.49K 10-Q · filed 2024-11-14 | $388.46K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$45.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $76.38K 10-Q · filed 2024-08-08 | $217.35K derived: sum of 3 quarters · filed 2024-08-08 | $253.19K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $122.24K 10-Q · filed 2024-05-14 | $263.20K derived: sum of 2 quarters · filed 2024-05-14 | $299.05K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $140.97K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $176.81K derived: sum of 2 quarters · filed 2024-03-26 | $206.86K 10-K · filed 2024-03-26 | |
| 2022-09-30 | $35.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $65.89K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $30.05K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |